Lyell Immunopharma (LYEL) M&A Announcement summary

Deal rationale and strategic fit

• Acquisition brings IMPT-314, a dual-targeting CD19/CD20 CAR T-cell candidate with strong phase 1 data, into the pipeline, addressing unmet needs in aggressive B-cell non-Hodgkin lymphoma and strengthening the focus on next-generation CAR T-cell therapies for hematologic malignancies.

• IMPT-314 is designed to improve complete response rates and duration over existing CD19 CAR therapies, with potential for significant market share in second- and third-line settings.

• The deal aligns with a strategic shift to prioritize next-generation CAR T-cell therapies for both hematologic malignancies and solid tumors, leveraging clinical, scientific, and manufacturing expertise.

• Provides upside potential in autoimmune indications and earlier-stage preclinical assets, supported by robust intellectual property.

• The acquisition is seen as a strong cultural and scientific fit, enabling acceleration of clinical development and manufacturing scale.

Financial terms and conditions

• Upfront consideration includes $30 million in cash and 37.5 million shares of common stock.

• Contingent consideration includes 12.5 million shares upon a predefined clinical milestone and a low single-digit royalty on U.S. sales upon commercialization.

• Transaction expected to close in Q4 2024 following Hart-Scott-Rodino clearance and customary closing conditions.

• The company maintains a strong balance sheet with $491 million in cash, providing runway into 2027 through multiple clinical milestones.

Synergies and expected cost savings

• The acquisition de-risks the product pipeline by adding a late-stage asset with compelling clinical data and accelerates the path to pivotal trial for IMPT-314/LYL314 in 2025.

• Operational streamlining includes discontinuation of less differentiated programs (LYL797, LYL845, and early-stage TILs) to focus resources on next-generation assets.

• Pipeline prioritization is expected to streamline operations and focus investment on differentiated CAR T-cell programs, supporting clinical milestones through 2027.